Nelfinavir . mesylate
| Code | Size | Price |
|---|
| AG-CR1-3726-M010 | 10 mg | £55.00 |
Quantity:
| AG-CR1-3726-M050 | 50 mg | £190.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
AG-1343; Nelfin; Viracept
Appearance:
White to off-white solid.
CAS:
159989-65-8
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1
InChiKey:
NQHXCOAXSHGTIA-SKXNDZRYSA-N
Long Description:
Chemical. CAS: 159989-65-8. Formula: C32H45N3O4S . CH4SO3. MW: 567.8 . 96.1. Nelfinavir is an orally bioavailable competitive inhibitor of the human immunodeficiency virus. It potently inhibits HIV-1 (Ki=2nM) and HIV-2 protease in vitro. HIV-1 protease is important for the replication of the virus within the cell and the release of mature viral particles from the infected cell. Formulations containing nelfinavir have been used in combination with HIV reverse transcriptase inhibitors for the treatment of AIDS. Nelfinavir shows other antimicrobial and antiviral activity. It inhibits maturation and export of the Herpes Simplex 1 virus and the Kaposi's Sarcoma virus, replication of SARS-CoV and also replication of SARS-CoV-2, cause for the epidemic COVID-19. Has potent anti-cancer activity against a broad selection fo cancer cell types. Shown to induce apoptosis, autophagy, cell cycle arrest and endoplasmic reticulum stress, which consequently leads to cancer cell death. Shown to inhibit the Akt/PKB signaling pathway. It acts as an antifibrotic agent and is used to treat pulmonary fibrosis in patients with systemic sclerosis (SSc) and reduces inflammation by activating protein phosphatase 2 (PP-2) and blocking mitogen-activated protein kinases (MAPK) signaling in macrophages.
MDL:
MFCD00931436
Molecular Formula:
C32H45N3O4S . CH4SO3
Molecular Weight:
567.8 . 96.1
Package Type:
Vial
Product Description:
Nelfinavir is an orally bioavailable competitive inhibitor of the human immunodeficiency virus. It potently inhibits HIV-1 (Ki=2nM) and HIV-2 protease in vitro. HIV-1 protease is important for the replication of the virus within the cell and the release of mature viral particles from the infected cell. Formulations containing nelfinavir have been used in combination with HIV reverse transcriptase inhibitors for the treatment of AIDS. Nelfinavir shows other antimicrobial and antiviral activity. It inhibits maturation and export of the Herpes Simplex 1 virus and the Kaposi's Sarcoma virus, replication of SARS-CoV and also replication of SARS-CoV-2, cause for the epidemic COVID-19. Has potent anti-cancer activity against a broad selection fo cancer cell types. Shown to induce apoptosis, autophagy, cell cycle arrest and endoplasmic reticulum stress, which consequently leads to cancer cell death. Shown to inhibit the Akt/PKB signaling pathway. It acts as an antifibrotic agent and is used to treat pulmonary fibrosis in patients with systemic sclerosis (SSc) and reduces inflammation by activating protein phosphatase 2 (PP-2) and blocking mitogen-activated protein kinases (MAPK) signaling in macrophages. It has also shown pan-proteasome inhibition in AMO-1 and U266 myeloma cells.
Purity:
>98% (HPLC)
SMILES:
O[C@@H]([C@H](CSC1=CC=CC=C1)NC(C2=C(C)C(O)=CC=C2)=O)CN3C[C@@]4([H])CCCC[C@@]4([H])C[C@H]3C(NC(C)(C)C)=O.CS(=O)(O)=O
Solubility Chemicals:
Soluble in DMSO (15mg/ml), DMF (20mg/ml) or ethanol (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease: S.W. Kaldor, et al.; J. Med. Chem. 40, 3979 (1997) | Nelfinavir mesylate: a protease inhibitor: V.B. Pai & M.C. Nahata; Ann. Pharmacother. 33, 325 (1999) (Review) | HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus: N. Yamamoto, et al.; BBRC 318, 719 (2004) | The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells: H. Bode, et al.; Antivir. Ther. 10, 645 (2005) | HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest: W. Jiang, et al.; Cancer Res. 67, 1221 (2007) | The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response: A.K. Gupta, et al.; Neoplasia 9, 271 (2007) | Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo: J.J. Gills, et al.; Clin. Cancer Res. 13, 5183 (2007) | New prospects for nelfinavir in non-HIV-related diseases: A. Bruning, et al.; Curr. Mol. Pharmacol. 3, 91 (2010) (Review) | Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes: P. Kumar, et al.; PLoS Negl. Trop. Dis. 4, e642 (2010) | The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro: S. Gantt, et al.; Antimicrob. Agents Chemother. 55, 2696 (2011) | The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation: M.A. Wallet, et al.; J. Leukoc. Biol. 92, 795 (2012) | Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir: J.S. Shim, et al.; J. Natl. Cancer Inst. 104, 1576 (2012) | The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo: C. Bono, et al.; Haematologica 97, 1101 (2012) | Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation: S. Gantt, et al.; Adv. Virol. 2015, 687162 (2015) | Systemic sclerosis: Antiviral drug inhibits lung fibrosis: J. McHugh; Nat. Rev. Rheumatol. 13, 696 (2017) (Review) | Nelfinavir is active against SARS-CoV-2 in Vero E6 cells: Z. Xu, et al.; ChemRxiv (Preprint) (2020) | Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro: N. Yamamoto, et al.; BioRxiv (Preprint) (2020) | Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation: Z. Xu, et al.; BioRxiv (Preprint) (2020)